Gene Single Nucleotide Polymorphism Accumulation Improves Survival in Advanced Head and Neck Cancer Patients Treated With Weekly Paclitaxel
Gene Single Nucleotide Polymorphism Accumulation Improves Survival in Advanced Head and Neck Cancer Patients Treated With Weekly Paclitaxel
复制标题
DOI：
10.1002/lary.20254
复制
发表时间：
2009-08-01
期刊：
影响因子：
2.6
通讯作者：
Monzo, Mariano
中科院分区：
文献类型：
--
作者：
Grau, Juan J.;Caballero, Miguel;Monzo, Mariano
目的/假设：药物代谢相关基因的单核苷酸多态(SNPs)与生存期相关。方法：我们研究了参与药物代谢的6个基因(CYP2C8、GSTT1、GSTP1、MDR1-57、MDR1-62和ERCC1)的单核苷酸多态(SNPs)的存在以及紫杉醇每周治疗晚期头颈癌患者的有效率(RR)、进展时间(TTP)和总生存率(OS)。结果：在本组患者中，CYP2C8、MDR1-57和MDR1-62基因的SNPs频率高于野生型基因。有效率为45%(21/47)，中位TTP为5.1个月。所有患者的OS均为5.6个月。与野生型基因相比，mdr1-62、mdr1-57或两个或两个以上累积基因的SNP的反应更高。有两个或两个以上SNPs累积的患者OS显著延长(P=.039)。结论：具有两个或两个以上SNPs累积的患者的有效率和OS显著较高。
Objectives/Hypothesis: Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival.Methods: We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel.Results: SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039).Conclusions: Response rate and OS were significantly higher in patients with two or more accumulated SNPs.